Company Encyclopedia
View More
name
Sutro Biopharma
STRO.US
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.
1.946 T
STRO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking375/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-1810.01%E
    • Profit Margin-205.18%E
    • Gross Margin-311.15%E
  • Growth ScoreE
    • Revenue YoY-34.36%E
    • Net Profit YoY-74.88%E
    • Total Assets YoY-53.60%E
    • Net Assets YoY-178.46%E
  • Cash ScoreE
    • Cash Flow Margin-48.74%D
    • OCF YoY-34.36%E
  • Operating ScoreD
    • Turnover0.32D
  • Debt ScoreE
    • Gearing Ratio141.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sutro Biopharma (NASDAQ:STRO) Shares Gap Up - What's Next?

    Sutro Biopharma's stock (NASDAQ:STRO) experienced a price gap up, opening at $7.75 from a previous close of $7.2980. Despite this, analysts have mixed ratings: Wall Street Zen downgraded it to 'sell', while Wedbush increased its price objective to $100. The company reported a Q3 loss of $0.67 per share, missing estimates. Institutional investors hold 96.99% of the stock. Sutro Biopharma focuses on oncology with products in various clinical trial phases.

    Market Beat·
    US
    STRO
    +7.82%
    Market Beat·
    US
    STRO
    +7.82%

    Sutro Biopharma (STRO) Receives a Buy from Piper Sandler

    Piper Sandler analyst Edward Tenthoff reiterated a Buy rating for Sutro Biopharma, setting a price target of $20. Despite Tenthoff's average return of -8.8% and a 33.95% success rate, Sutro Biopharma has a Moderate Buy consensus with a price target of $6.70.

    Tip Ranks·
    US
    STRO
    +7.82%
    Tip Ranks·
    US
    STRO
    +7.82%

    Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush

    Wedbush reiterated a "neutral" rating for Sutro Biopharma, raising its price target from $2.00 to $10.00. Other analysts have varied ratings, with Wall Street Zen downgrading to "sell" and Wells Fargo reducing its price target. Sutro Biopharma's stock is trading down, with a reverse split planned. Institutional investors hold 96.99% of shares, and insider buying has occurred recently.

    Market Beat·
    US
    STRO
    +7.82%
    Market Beat·
    US
    STRO
    +7.82%

    Sutro Biopharma Enacts 1-for-10 Reverse Stock Split

    Sutro Biopharma Inc. announced a 1-for-10 reverse stock split effective December 3, 2025. Post-split, shares will trade under the symbol 'STRO' with a new CUSIP number. The split reduces outstanding shares from 85.2 million to 8.5 million to meet Nasdaq's minimum bid price requirement. Adjustments will be made to equity awards and share plans.

    Reuters·
    US
    STRO
    +7.82%
    Reuters·
    US
    STRO
    +7.82%

    Sutro Biopharma Doses First Patients in Phase 1 Trial of STRO-004 for TF-Expressing Solid Tumors

    Sutro Biopharma Inc. has commenced a Phase 1 clinical trial for STRO-004, a TF-targeting antibody drug conjugate, in patients with advanced TF-expressing solid tumors. The trial will evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across various cancer types. Initial data is expected by mid-2026. This announcement was originally published by Sutro Biopharma via GlobeNewswire.

    Reuters·
    US
    STRO
    +7.82%
    Reuters·
    US
    STRO
    +7.82%
    © 2025 Longbridge｜Disclaimer